Avacta (AIM: AVCT) has enjoyed a strong recovery in sentiment during the second half of 2025, with the share price rising from around 30 pence in early July to 58.00 pence
Avacta (AIM: AVCT) has enjoyed a strong recovery in sentiment during the second half of 2025, with the share price rising from around 30 pence in early July to 58.00 pence
Avacta reports new pharmacology data for FAP-Exd (AVA6103) Multiple patient-derived xenograft models with prolonged complete responses associated with sustained release of the exatecan payload within the tumor over five days
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society
Avacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort
Welcome to the Avetix Group YouTube channel.
Hemogenyx Pharmaceuticals (LON: HEMO) has received clearance from its independent Data Safety Monitoring Board (DSMB) to proceed to the next adult dose level in its Phase I clinical trial of
Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets
Avacta Therapeutics presents compelling Phase 1a data for faridoxorubicin and the pre|CISION® platform at the European Society of Medical Oncology Annual Congress
Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium
Hemogenyx Pharmaceuticals Signs Letter of Intent with Cellin Technologies to Advance Commercialization of HG-CT-1 CAR-T Therapy in Estonia First Potential Near-Term Revenue Opportunity
Hemogenyx Pharmaceuticals has announced encouraging progress in its Phase I clinical trial of HG-CT-1, a CAR-T cell therapy targeting relapsed/refractory acute myeloid leukemia (AML) in adults.
Avacta Group plc has announced that its proprietary pre|CISION® platform has been shortlisted for the AIM Technology of the Year Award.